RT @jessrzanotti
@TumorBoardTues 3/15 #TumorBoardTuesday #NETCancer @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD

👩🏻 DP mediastinal LN after 6 mo
💉4L: FOLFIRINOX with partial response/severe toxicity
📑NGS (Foundation One): very high TMB 97 MSS

🧐What 5L tx would you pick?

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay

RT @RachelRiechelm2
@jessrzanotti @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc G3 #NETCancer: usually low TMB and distinct molecular profile from neuroendocrine carcinoma
DOI: 10.1111/jne.13099

RT @RachelRiechelm2
@jessrzanotti @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc Hypermutation , in our experience, it occurs in about 10% of #NETCancer post alkylating drugs

RT @jessrzanotti
@TumorBoardTues 3/15 #TumorBoardTuesday #NETCancer @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD

👩🏻 DP mediastinal LN after 6 mo
💉4L: FOLFIRINOX with partial response/severe toxicity
📑NGS (Foundation One): very high TMB 97 MSS

🧐What 5L tx would you pick?

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay

RT @jessrzanotti
@TumorBoardTues 3/15 #TumorBoardTuesday #NETCancer @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD

👩🏻 DP mediastinal LN after 6 mo
💉4L: FOLFIRINOX with partial response/severe toxicity
📑NGS (Foundation One): very high TMB 97 MSS

🧐What 5L tx would you pick?

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay

RT @RachelRiechelm2
@jessrzanotti @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc G3 #NETCancer: usually low TMB and distinct molecular profile from neuroendocrine carcinoma
DOI: 10.1111/jne.13099

RT @jessrzanotti
@TumorBoardTues 3/15 #TumorBoardTuesday #NETCancer @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD

👩🏻 DP mediastinal LN after 6 mo
💉4L: FOLFIRINOX with partial response/severe toxicity
📑NGS (Foundation One): very high TMB 97 MSS

🧐What 5L tx would you pick?

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay

RT @RachelRiechelm2
@TumorBoardTues Tx sequencing G3 #NETCancer often similar to G2 tumors- DOI: 10.1177/17588359231156218

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay

RT @jessrzanotti
@TumorBoardTues 3/15 #TumorBoardTuesday #NETCancer @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD

👩🏻 DP mediastinal LN after 6 mo
💉4L: FOLFIRINOX with partial response/severe toxicity
📑NGS (Foundation One): very high TMB 97 MSS

🧐What 5L tx would you pick?

RT @letswinpc
Tonight on #TumorBoardTuesday they're discussing a pancreatic neuroendocrine tumor case. Join the chat and get CME credit! #NETCancer #PancreaticCancer https://twitter.com/jessrzanotti/status/1653549758072471553

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay

RT @jessrzanotti
@TumorBoardTues 3/15 #TumorBoardTuesday #NETCancer @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD

👩🏻 DP mediastinal LN after 6 mo
💉4L: FOLFIRINOX with partial response/severe toxicity
📑NGS (Foundation One): very high TMB 97 MSS

🧐What 5L tx would you pick?

RT @RachelRiechelm2
@jessrzanotti @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc G3 #NETCancer: usually low TMB and distinct molecular profile from neuroendocrine carcinoma
DOI: 10.1111/jne.13099

RT @letswinpc
Tonight on #TumorBoardTuesday they're discussing a pancreatic neuroendocrine tumor case. Join the chat and get CME credit! #NETCancer #PancreaticCancer https://twitter.com/jessrzanotti/status/1653549758072471553

RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD 4/15 #TumorBoardTuesday #NETCancer
Due to findings👆🏽

💉 Systemic therapy modified to Pembrolizumab

See image for full biomarker assay